Losartan Potassium
Product Images NDC 68151-0183

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68151-0183). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure01 (Figure01)

A line graph comparing the percentage of patients reaching a primary endpoint over 66 months between Atenolol (dotted line) and Losartan Potassium (solid line). The x-axis represents study months, and the y-axis shows the percentage of patients with the primary endpoint. The graph includes a note of an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Figure02 (Figure02)

A line chart comparing the percentage of patients with fatal/non-fatal stroke over a study period of 66 months between Atenolol (dotted line) and Losartan Potassium (solid line). The chart shows a lower stroke incidence in patients treated with Losartan Potassium, with an adjusted risk reduction of 25% (p=0.001). The x-axis represents study months, and the y-axis represents the percentage of patients with fatal or non-fatal stroke.*

FDA Label Image

Figure03 (Figure03)

A comparative hazard ratio forest plot chart showing the event rates for Losartan Potassium versus Atenolol. The chart presents data on primary composite outcomes and stroke (fatal/non-fatal) incidence across various patient subgroups, including age, gender, race, isolated systolic hypertension (ISH), diabetes status, and history of cardiovascular disease (CVD). The horizontal axis indicates hazard ratios favoring either Losartan K or Atenolol, with symbols proportional to sample sizes.*

FDA Label Image

Figure04 (Figure04)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and placebo groups. The graph shows two lines, one solid for Losartan Potassium and one dashed for placebo, indicating a 16.1% risk reduction for Losartan Potassium with a p-value of 0.022.*

FDA Label Image

Label Image (Lbl681510183)

Losartan Potassium 50 mg tablet label showing the active ingredient and strength, manufacturer as TEVA, lot number, expiration date (11/14), and prescription-only designation. The label includes a barcode and product NDC 68151-0183 from Carilion Materials Management.*

FDA Label Image

Structure (Structure)

Chemical structure of Losartan Potassium, showing its molecular arrangement including a chlorinated heterocyclic ring, a hydroxymethyl group, and a potassium ion (K+). The structural diagram highlights the chemical connectivity and functional groups of the active pharmaceutical ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.